



Application to become a DPUK Consortium Partner

Contacts:

Professor John Gallacher (Director) John.Gallacher@psych.ox.ac.uk	Dr Simon Young (Senior Project Manager) Simon.Young@psych.ox.ac.uk
--	--

Website: <https://www.dementiasplatform.uk/>

Background

Dementia affects over 50 million people globally and yet to date there are no successful treatments. In 2014 the MRC launched Dementias Platform UK (DPUK) to revolutionise dementia studies and cohort research, as dementia is the leading cause of death in the UK.

DPUK is a public-private partnership funded by the Medical Research Council (MRC) which aims to accelerate the development of new treatments for dementia. The focus is on the detection and treatment of dementia earlier than ever before.

DPUK is transforming research through partnering with Universities, the National Institute for Health Research (NIHR), industry/biotech and Third Sector (charities). In addition, DPUK has developed expert technology networks - imaging, stem cell and informatics – to increase our understanding of how dementia starts.

DPUK2 (January 2021-December 2025) focuses on developing UK capacity for dementia experimental medicine. It has three inter-dependent work streams

The **Data Portal** gives researchers rapid online access to unprecedented amounts of cohort data – genetics, imaging and medical records of over 3 million participants. This is generating new insights into ageing, diseases, and dementia risk.

The **Trials Delivery Framework** will create an integrated clinical research environment optimised for the rapid and effective delivery of high quality EM in both pre-clinical and early dementia. Specifically, it will organise DPUK's Clinical Studies Register to facilitate cohort members volunteering for experimental medicine studies.

The **Experimental Medicine Incubator** will nurture academic-industry partnerships for precision mechanistic EM Studies. Three areas have been chosen for initial focus, Vascular Health, Synaptic Health and Neuroimmunology. DPUK2 will develop this EM portfolio according to scientific interest and the availability of further funding.

Current studies are breaking new ground using stem cell, imaging, and informatics technologies (see final reports on the DPUK website: <https://www.dementiasplatform.uk/about-us/our-achievements/research-project-reports>). This is increasing the scale and rigor of trials, adding to our knowledge of how dementia starts and where to target treatments.

Benefits of being a partner in the DPUK Consortium

The key benefits of being a partner in the DPUK consortium are:

- having strategic input into the development of the work packages in the programme;
- involvement in the design of additional studies;
- participation in networking with representatives from Large Pharma, Biotech companies and academia.

Becoming a partner in the DPUK Consortium

Prospective partners need to decide whether to apply to become Full Partners or Associate Partners. The level of contribution to the work performed, and provided by the partner as cash or in-kind support, is different for full and Associate Partners (see below).

An “Associate Partner” is a for-profit Third Party that undertakes work in conjunction with, or otherwise provides contributions to, an Academic Partner in support of such Academic Partner’s work under a specific Workstream or Workpackage only. Associate Partners are not entitled to nominate a representative to sit on the Partner Forum.

Contributions expected to be offered by Partners

FULL PARTNERS

The agreed contributions for full partners in the Consortium Agreement as cash or in-kind support are as follows. Further information below will inform as to which category a proposed partner falls into.

SME- £250,000 (over the 5 years of the Consortium Agreement)

Large Pharma- £1,000,000 (over the 5 years of the Consortium Agreement).

Mid- Cap- £600,000 (over the 5 years of the Consortium Agreement).

Large pharma would be any organisation that does not fit into the SME or Mid-cap qualification. For private mid-cap companies that are not listed or quoted on any stock exchange, the audited revenue from the last financial year and employee figures must both be true, and market cap doesn't apply.

Criterion	SME	Mid Cap
Employees	<250	250-2500
Turnover	<€50M	<€1000M
Balance sheet	<€43M	
Market Cap		€1bn-€5bn

ASSOCIATE PARTNERS

An Associate Partner’s contribution should be typically 50% of the relevant full partner contribution

This would equate to:

SME- £125,000 (over the 5 years of the Consortium Agreement)

Large Pharma- £500,000 (over the 5 years of the Consortium Agreement).

Mid- Cap- £300,000 (over the 5 years of the Consortium Agreement).

Process for formally applying to be a DPUK Partner:

A formal case should be prepared for approval as described in DPUK Governance (DPUK Consortium Agreement).

The case must include the following as a minimum:

- a. Background details on the partner, including its sphere of operation and how it believes it can contribute to the mission and objectives of DPUK;
- b. Proposed contribution from partner to DPUK:
 - Summary of proposed (scientific) involvement;
 - Summary of proposed cash or in-kind contributions. There are defined levels of contributions required (see above);
- c. Proposed contribution from DPUK to partner:
 - A statement describing what the partner believes it will gain from involvement in the DPUK Consortium;
 - Details of any in-kind contribution that will be available to the partner from DPUK (this may not always be relevant).

Additional supporting information such as figures, examples and diagrams can be used to enhance the case. Publications or equivalent (with DOIs or links) may also be provided.

This documentation should be sent to **simon.young@psych.ox.ac.uk**